<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146340</url>
  </required_header>
  <id_info>
    <org_study_id>042-2010</org_study_id>
    <nct_id>NCT01146340</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer</brief_title>
  <official_title>Phase I/II Study of Dose-Escalated Hypofractionated Radiotherapy for Low- and Intermediate-Risk Prostate Cancer (PHART6)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Association of Radiation Oncology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of a short course of
      radiotherapy (40 Gy / 5 fractions / 29 days) for the treatment of low- and intermediate-risk
      prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 3+ rectal toxicity</measure>
    <time_frame>Acute period (&lt;3 months)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3+ urinary toxicity</measure>
    <time_frame>Acute (&lt;3 months) and Late (&gt;6 months)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 years</time_frame>
    <description>Expanded Prostate Cancer Index Composite (EPIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical (ie. prostate specific antigen) disease free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3+ rectal toxicity</measure>
    <time_frame>Late (&gt;6 months)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT 40 Gy in 5 fractions over 29 days delivered using step and shoot IGRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiotherapy</intervention_name>
    <description>40 Gy / 5 fractions / 29 days</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men &gt;18 years

          -  Histologically confirmed prostate adenocarcinoma

          -  Low or low-intermediate risk prostate cancer, defined as Clinical stage T1-2b, Gleason
             Score &lt;=6, and PSA &lt;15 ng/mL, OR Clinical stage T1-2b, Gleason Score 7, and PSA &lt;=10
             ng/mL

        Exclusion Criteria:

          -  Prior pelvic radiotherapy

          -  Anticoagulation medication (if unsafe to discontinue for gold seed insertion)

          -  Diagnosis of bleeding diathesis

          -  Presence of a hip prosthesis

          -  Pelvic girth &gt;40cm - Large prostate (&gt;90cm3) on imaging

          -  Severe lower urinary tract symptoms (International Prostate Symptom Score &gt;19 or
             nocturia &gt;3)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Loblaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harvey Quon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>April 22, 2016</last_update_submitted>
  <last_update_submitted_qc>April 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Andrew Loblaw</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Hypofractionation</keyword>
  <keyword>Low and Intermediate Risk Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

